|
|
BioSAFE ? Biomarkers in Sleep Apnea Syndrome as Future Predictor of Efficacy of cPAP Therapy
| Third-party funded project |
| Project title |
BioSAFE ? Biomarkers in Sleep Apnea Syndrome as Future Predictor of Efficacy of cPAP Therapy |
| Principal Investigator(s) |
Stolz, Daiana
|
| Organisation / Research unit |
Bereich Medizinische Fächer (Klinik) / Pneumologie (Stolz) |
| Project start |
01.01.2011 |
| Probable end |
31.12.2013 |
| Status |
Completed |
| Abstract |
Hypoxic stimuli have been shown to increase circulating vasopressin concentrations. Plasma levels of ADM have been shown to be increased in a number of pathological states, including congestive heart failure, sepsis, essential hypertension, acute myocardial infarction, and renal impairment. Atrial natriuretic peptide (ANP) synthesis and secretion is increased during hypoxic exposure and plays an important role in the normal adaptation to hypoxia and in the pathogenesis of cardiopulmonary diseases, including chronic hypoxia-induced pulmonary hypertension and vascular remodelling, and right ventricular hypertrophy and right heart failure.
A) To quantify circulating copeptin, Pro-ANP and Pro-ADM levels in patients with obstructive sleep apnoea syndrome (OSAS) before and under treatment with continuous positive airway pressure (CPAP) respectively.
B) To evaluate whether circulating copeptin, Pro-ANP and Pro-ADM levels correlate with severity of OSAS and whether changes in these levels correlate with the response to treatment.
Prospective, observational longitudinal single centre study
Hypoxic stimuli have been shown to increase circulating vasopressin concentrations. Plasma levels of ADM have been shown to be increased in a number of pathological states, including congestive heart failure, sepsis, essential hypertension, acute myocardial infarction, and renal impairment. Atrial natriuretic peptide (ANP) synthesis and secretion is increased during hypoxic exposure and plays an important role in the normal adaptation to hypoxia and in the pathogenesis of cardiopulmonary diseases, including chronic hypoxia-induced pulmonary hypertension and vascular remodelling, and right ventricular hypertrophy and right heart failure.
A) To quantify circulating copeptin, Pro-ANP and Pro-ADM levels in patients with obstructive sleep apnoea syndrome (OSAS) before and under treatment with continuous positive airway pressure (CPAP) respectively.
B) To evaluate whether circulating copeptin, Pro-ANP and Pro-ADM levels correlate with severity of OSAS and whether changes in these levels correlate with the response to treatment.
Prospective, observational longitudinal single centre study |
| Financed by |
Private Sector / Industry
|
| |
|
|
MCSS v5.8 PRO. 0.443 sec, queries - 0.000 sec
©Universität Basel | Impressum
|  |
|
05/05/2024
Research Database / FORSCHUNGSDATENBANK
|
